Hsp27 and Hsp70 administered in combination have a potent protective effect against FALS-associated SOD1-mutant-induced cell death in mammalian neuronal cells

Brain Res Mol Brain Res. 2005 Apr 4;134(2):256-74. doi: 10.1016/j.molbrainres.2004.10.028. Epub 2004 Dec 15.

Abstract

Amyotrophic lateral sclerosis (ALS) is an adult-onset degenerative disorder characterised by the death of motor neurons in the cortex, brainstem, and spinal cord; resulting in progressive muscle weakness, atrophy, and death from respiratory paralysis, usually within 3-5 years of symptom onset. Approximately 10% of ALS cases are familial (FALS). Mutations in superoxide dismutase-1 (SOD1) cause approximately 20% of FALS cases and there is overwhelming evidence that a toxic gain of function is the cause of the disease. We have previously shown that FALS-associated SOD1 disease mutants enhanced neuronal death in response to a wide range of stimuli tested whereas wt-SOD1 protected against all insults. We demonstrate for the first time that over-expression of either heat shock protein Hsp27 or Hsp70 has a protective effect against SOD1 disease associated mutant-induced cell death. However, over-expression of Hsp27 and Hsp70 together has a greater potent anti-apoptotic effect, than when expressed singly, against the damaging effects of mutant SOD1. Our results indicate that FALS-associated SOD1 disease mutants possess enhanced death-inducing properties and lead to increased apoptosis which can be prevented by either the use of specific caspase inhibitors or Hsp27 and/or Hsp70 over-expression. This potent protective effect of Hsp27 and Hsp70 against the FALS-associated SOD1 disease mutants may be of potential therapeutic importance.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Chloromethyl Ketones / pharmacology
  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / pathology
  • Amyotrophic Lateral Sclerosis / physiopathology
  • Amyotrophic Lateral Sclerosis / prevention & control*
  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Blotting, Western / methods
  • Cell Death / drug effects
  • Cell Death / genetics
  • Cells, Cultured
  • Cricetinae
  • Culture Media, Serum-Free / pharmacology
  • Disease Models, Animal
  • Drug Combinations
  • Drug Interactions
  • Enzyme Inhibitors / pharmacology
  • Ganglia, Spinal / cytology*
  • Genetic Vectors / physiology
  • Green Fluorescent Proteins / metabolism
  • HIV-1 / physiology
  • HSP27 Heat-Shock Proteins
  • HSP70 Heat-Shock Proteins / administration & dosage*
  • Heat-Shock Proteins / administration & dosage*
  • In Situ Nick-End Labeling / methods
  • Mutagenesis / physiology
  • Mutation
  • Neoplasm Proteins / administration & dosage*
  • Neurons / drug effects*
  • Neuroprotective Agents / pharmacology
  • Rats
  • Staurosporine / pharmacology
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase-1
  • Time Factors
  • Transfection / methods

Substances

  • Amino Acid Chloromethyl Ketones
  • Culture Media, Serum-Free
  • Drug Combinations
  • Enzyme Inhibitors
  • HSP27 Heat-Shock Proteins
  • HSP70 Heat-Shock Proteins
  • Heat-Shock Proteins
  • Hspb1 protein, rat
  • Neoplasm Proteins
  • Neuroprotective Agents
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • Green Fluorescent Proteins
  • Sod1 protein, rat
  • Superoxide Dismutase
  • Superoxide Dismutase-1
  • Staurosporine